DDInter1137 DDInter1658
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Medrysone
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Hydrocortamate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
Medroxyprogesterone acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) USP22
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Palpitations
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Medroxyprogesterone acetate (Compound) resembles Hydrocortamate (Compound)
Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene)
Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease)
Medroxyprogesterone acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Medroxyprogesterone acetate (Compound) downregulates USP22 (Gene)
Medroxyprogesterone acetate (Compound) causes Palpitations (Side Effect)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Delavirdine